The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its ...